BCMA is highly expressed on myeloma cells and has been identified as a ... LB1901 targets CD4, a surface membrane glycoprotein that is expressed in most TCL subtypes. Legend Biotech is also ...

The bispecific BCMA-CD19 CAR-T cells containing anti-BCMA single chain variable fragment (scFv) and anti-CD19 scFv in tandem, linked by GGGGS×4, could cover almost all stages of the B-cell ...

is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein commonly found on the surface of the malignant B-cells that cause the disease. It is the first ...

employed mRNA and lipid nanoparticle technologies to modify the surface of BCMA CAR T cells to re-direct their trafficking to the myeloma-tumor site, minimizing dose-related cytotoxic effects such as ...

Verified GEMs range from cell surface receptors to intracellular signaling ... including GEM-enhanced CD19 and BCMA CAR-T cell therapies for patients relapsed from first-generation CAR-T treatments.

CDR111, CDR-Life’s newest clinical candidate, is a trispecific molecule targeting CD19, BCMA and CD3, designed to achieve immune reset through broad B cell depletion. This novel therapeutic ...